GLP-1 agonist drugs like Zepbound and Mounjaro from drugmaker Eli Lilly (LLY 2.95%) continue to rise in popularity as people are hopeful about the weight loss they can achieve with their help.

As of 2024, Medicare Part D covers Ozempic, Mounjaro, Rybelsus (semaglutide), and Wegovy for FDA-approved conditions. But they are not covered for weight loss.

As of 2024, Medicare Part D covers Ozempic, Mounjaro, Rybelsus (semaglutide), and Wegovy for FDA-approved conditions. But they are not covered for weight loss.

Healthcare providers often prescribe GLP-1 drugs such as semaglutide (Ozempic and Wegovy) or liraglutide (Victoza and Saxenda) for type 2 diabetes control and weight loss.

Zepbound (tirzepatide) and Mounjaro (tirzepatide) are also common treatments in a class known as glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists. Some GLP-1 agonists, like ...